Optimization of risk stratification for anticoagulation-associated intracerebral hemorrhage: net risk estimation

Background Every anticoagulation decision has in inherent risk of hemorrhage; intracerebral hemorrhage (ICH) is the most devastating hemorrhagic complication. We examined whether combining ischemic and hemorrhagic stroke risk in individual patients might provide a meaningful paradigm for risk strati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of neurology 2020-04, Vol.267 (4), p.1053-1062
Hauptverfasser: Lioutas, Vasileios-Arsenios, Goyal, Nitin, Katsanos, Aristeidis H., Krogias, Christos, Zand, Ramin, Sharma, Vijay K., Varelas, Panayiotis, Malhotra, Konark, Paciaroni, Maurizio, Karapanayiotides, Theodore, Sharaf, Aboubakar, Chang, Jason, Kargiotis, Odysseas, Pandhi, Abhi, Palaiodimou, Lina, Schroeder, Christoph, Tsantes, Argyrios, Boviatsis, Efstathios, Mehta, Chandan, Serdari, Aspasia, Vadikolias, Konstantinos, Mitsias, Panayiotis D., Selim, Magdy H., Alexandrov, Andrei V., Tsivgoulis, Georgios
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Every anticoagulation decision has in inherent risk of hemorrhage; intracerebral hemorrhage (ICH) is the most devastating hemorrhagic complication. We examined whether combining ischemic and hemorrhagic stroke risk in individual patients might provide a meaningful paradigm for risk stratification. Methods We enrolled consecutive patients with anticoagulation-associated ICH in 15 tertiary centers in the USA, Europe and Asia between 2015 and 2017. Each patient was assigned baseline ischemic stroke and hemorrhage risk based on their CHA 2 DS 2 -VASc and HAS-BLED scores. We computed a net risk by subtracting hemorrhagic from ischemic risk. If the sum was positive the patient was assigned a “Favorable” indication for anticoagulation; if negative, “Unfavorable”. Results We enrolled 357 patients [59% men, median age 76 (68–82) years]. 31% used non-vitamin K antagonist (NOAC). 191 (53.5%) patients had a favorable indication for anticoagulation prior to their ICH; 166 (46.5%) unfavorable. Those with unfavorable indication were younger [72 (66–80) vs 78 (73–84) years, p  = 0.001], with lower CHA 2 DS 2 -VASc score [3(3–4) vs 5(4–6), p 
ISSN:0340-5354
1432-1459
DOI:10.1007/s00415-019-09678-2